LXRX - NASDAQ

Lexicon Pharmaceuticals, Inc.

LXRX·NASDAQ

$1.94

+2.4%

HealthcareBiotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$859.52M

EPS-0.1400

P/E Ratio-13.82

Earnings Date07/30/2026

lxrx

Other Current Liabilities

Last Annual Value

11.55M

3-Year CAGR

47%

5-Year CAGR

13%

10-Year CAGR

Adjust for Inflation

Lexicon Pharmaceuticals, Inc. Competitors Analysis of Other Current Liabilities

LXRX · NASDAQ

Company	Other Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX	11.55M	6.4%	15.1%	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	6.78M	-5.0%	18.3%	N/A
Ocugen, Inc. NASDAQ:OCGN	6.69M	86.7%	31.3%	18.4%
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	28.79M	41.6%	28.8%	N/A
4D Molecular Therapeutics, Inc. NASDAQ:FDMT	26.87M	90.9%	N/A	N/A
Fulcrum Therapeutics, Inc. NASDAQ:FULC	9.05M	183.8%	14.0%	N/A
Compass Therapeutics, Inc. NASDAQ:CMPX	11.38M	80.4%	48.0%	N/A
Gossamer Bio, Inc. NASDAQ:GOSS	56.53M	76.4%	36.5%	N/A
Omeros Corporation NASDAQ:OMER	48.79M	N/A	67.4%	18.9%

Lexicon Pharmaceuticals, Inc. Fair Value Envelope

LXRX · NASDAQ

Our analysis suggests that LXRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.935, this represents a potential HIDDEN relative to our calculated worth for Lexicon Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.935

Related Guides

Blog Categories

Continue your LXRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.